This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
MEDNAX's (MD) Strategic Initiatives to Streamline Operations
by Zacks Equity Research
MEDNAX (MD) declares several transformational activities, which augur well for the long term.
Why Should You Hold on to Tenet Healthcare (THC) Stock?
by Zacks Equity Research
Despite the recent drag in Tenet Healthcare's (THC) business volumes, the same is expected to bounce back, given its solid fundamentals and the strategic initiatives taken.
Why Is Universal Health Services (UHS) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Should You Hold onto Acadia Healthcare Stock?
by Sapna Bagaria
Despite the recent drag in Acadia Healthcare's (ACHC) business volumes, the same is expected to bounce back, given the defensive demand for its mental and behavioral health business.
MEDNAX Divests American Anesthesiology to Avoid Cash Losses
by Zacks Equity Research
MEDNAX (MD) sells its American Anesthesiology to NAPA for portfolio rationalization and averting the negative COVID-19 impact.
MEDNAX's (MD) Earnings Miss Estimates in Q1, Tumble Y/Y
by Zacks Equity Research
MEDNAX's (MD) Q1 results reflect the coronavirus adversities that drained its revenues and volumes.
Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates
by Zacks Equity Research
Universal Health's (UHS) first-quarter earnings reflect pre-tax unrealized loss and higher expenses.
Universal Health Services (UHS) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of -33.20% and -2.84%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Universal Health's (UHS) Q1 Earnings: What is in Store?
by Zacks Equity Research
Universal Health's (UHS) first-quarter results are likely to reflect better revenues, partially offset by the COVID-19 impact.
MEDNAX Plunges More Than 54% YTD: Will the Stock Rebound?
by Zacks Equity Research
Even though MEDNAX (MD) endures the COVID-19 impact on global economy, it holds high prospects to revive its fortunes by virtue of its solid fundamentals.
Community Health Repeals 2020 Outlook Amid Coronavirus Woes
by Zacks Equity Research
Community Health (CYH) withdraws its current-year guidance amid prevalent market volatility induced by the COVID-19 spread.
Universal Health Plunges 31.4% YTD: Will It Bounce Back?
by Zacks Equity Research
Even though Universal Health (UHS) suffers the COVID-19 impact on global economy, it holds potential to stage a comeback by virtue of its solid fundamentals.
Tenet Healthcare (THC) Gets Rating Actions From Moody's
by Zacks Equity Research
Tenet Healthcare (THC) gets specific rating actions from credit rating agency Moody's. The outlook of the ratings is stable.
Tenet Heathcare Scraps Q1 & 2020 Guidance Amid Coronavirus Chaos
by Zacks Equity Research
Tenet Heathcare (THC) nullifies its first-quarter and 2020 outlook due to the COVID-19 pandemic.
Universal Health Services (UHS) Down 28.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Universal Health Services (UHS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MEDNAX Withdraws Q1 & 2020 Guidance Due to Coronavirus Woes
by Zacks Equity Research
MEDNAX (MD) takes back its first-quarter 2020 and preliminary full-year outlook due to the COVID-19 effect.
Coronavirus-Hit Hospital Stocks Gain on Senate Stimulus Help
by Sapna Bagaria
The stimulus bill will offer the much-required financial relief to COVID-19-plagued hospitals and lead to their share price appreciation.
Acadia Healthcare Cancels U.K. Unit Sale on Coronavirus Crisis
by Zacks Equity Research
Acadia Healthcare (ACHC) dismisses plan to sell its U.K. business due to the economic uncertainty caused by coronavirus outbreak.
Tenet Healthcare Down 60.6% YTD: Should You Buy the Dip?
by Zacks Equity Research
Tenet Healthcare (THC) stock down following recommendations to keep elective procedures on hold due to coronavirus outbreak.
Chips Are Down for Hospitals on Coronavirus-Led Business Woes
by Sapna Bagaria
Stocks of hospital companies display a persistent downtrend as they put elective procedures on a back burner to brace up for the fight against a potential spike in coronavirus cases.
Universal Health Continues to Bank on Segmental Benefits
by Zacks Equity Research
Universal Health (UHS) thrives on its strong Acute Care and Behavioral platform segments.
Acadia Healthcare Gains From UK Unit Sale, Solid US Business
by Zacks Equity Research
Acadia Healthcare (ACHC) is well poised for growth on several organic and inorganic growth efforts in U.S. business and the ongoing sale proceedings of U.K. operations.
Universal Health's (UHS) Q4 Earnings Surpass, Improve Y/Y
by Zacks Equity Research
Universal Health's (UHS) Q4 results reflect higher revenues and solid segmental contributions.
Universal Health Services (UHS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Universal Health Services (UHS) delivered earnings and revenue surprises of 6.90% and 0.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
What in Store for Universal Health's (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.